ArticleEpidemiology and infection2020
Extended-spectrum beta-lactamase
Article in Epidemiology and infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 66 citations in OpenAlex.
- Urinary Tract Infections in Children - Microbiological Challenges and Mechanisms of Bacterial Resistance.Maedica · 2026Review
- Observational
- Deep Learning-Based Rapid Identification ofRisk management and healthcare policy · 2026Article
- Prevalence and Antimicrobial Resistance ofInfection and drug resistance · 2026Article
- Analysis of Antimicrobial Use and Bacterial Susceptibility in Patients with Urinary Tract Infections at a Certain Hospital From 2021 to 2023: A Retrospective Cohort Study.International journal of general medicine · 2026Article
- Microbiological profile and epidemiological perspective on urinary tract infections (UTIs) in a tertiary medical center in Western Mexico.Frontiers in microbiology · 2026Article
- Prevalence of Urinary Tract Infections Caused by Extended-Spectrum β-LactamaseInfection and drug resistance · 2026Article
- Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial Resistance in Urinary Tract Infections Among Patients with and Without Renal Comorbidities: A Retrospective Study from Al-Baha, Saudi Arabia.Pathogens (Basel, Switzerland) · 2025Article
- Rising Prevalence of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Bacterial profile and antibiotic resistance pattern of uropathogens isolated from patients with complicated urinary tract infections in a tertiary care hospital in Dhaka, Bangladesh.BMC infectious diseases · 2025Article
- Clinical impacts and management of urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a narrative review.Childhood kidney diseases · 2025Review
- Comprehensive analysis of beta-lactamase genes in clinical strains of Escherichia coli and Klebsiella pneumoniae: molecular characterization, and in Silico predictions.Journal of computer-aided molecular design · 2025Article
- Controversies in treating febrile infantile urinary tract infection caused by extended-spectrum beta-lactamase producing Enterobacteriaceae: an international multi-centre survey.Pediatric nephrology (Berlin, Germany) · 2025Article
- Fosfomycin resistance in extended-spectrum beta-lactamase producingJournal of medical microbiology · 2025Article
- Reshaping Resistance: How Autovaccine Therapy Alters the Course of Recurrent Multidrug-Resistant Urinary Tract Infections.Life (Basel, Switzerland) · 2025Article
- Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistantFrontiers in microbiology · 2025Article
- Susceptibility of various Gram-negative bacteria to antibacterial agents: SMART in China 2019-2020.BMC microbiology · 2024Article
- Prevalence, Risk Factors and Antibiotic Resistance of Extended-Spectrum Beta-Lactamase-ProducingChildren (Basel, Switzerland) · 2024Article
- The Impact of Urinary Catheterization on the Antibiotic Susceptibility of ESBL-Producing Enterobacterales: A Challenging Duo.Antibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae urinary tract infections (UTIs) is increasing worldwide. We investigated the prevalence, clinical findings, impact and risk factors of ESBL E. coli/K. pneumoniae UTI through a retrospective review of the medical records of children with UTI aged <15 years admitted to Prince of Songkla University Hospital, Thailand over 10 years (2004-2013). Thirty-seven boys and 46 girls had ESBL-positive isolates in 102 UTI episodes, compared with 85 boys and 103 girls with non-ESBL isolates in 222 UTI episodes. The age of presentation and gender were not significantly different between the two groups. The prevalence of ESBL rose between 2004 and 2008 before plateauing at around 30-40% per year, with a significant difference between first and recurrent UTI episodes of 27.3% and 46.5%, respectively (P = 0.003). Fever prior to UTI diagnosis was found in 78.4% of episodes in the non-ESBL group and 61.8% of episodes in the ESBL group (P = 0.003). Multivariate analysis indicated that children without fever (odds ratio (OR) 2.14, 95% confidence interval (CI) 1.23-3.74) and those with recurrent UTI (OR 2.67, 95% CI 1.37-5.19) were more likely to yield ESBL on culture. Congenital anomalies of the kidney and urinary tract were not linked to the presence of ESBL UTI. In conclusion, ESBL producers represented one-third of E. coli/K. pneumoniae UTI episodes but neither clinical condition nor imaging studies were predictive of ESBL infections. Recurrent UTI was the sole independent risk factor identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.